Skip to main content
Clinical Trials/NCT06026735
NCT06026735
Recruiting
Not Applicable

Comprehensive Profiling of Promising Biomarkers in Exosomes From Non-small Cell Lung Cancer With Central Nervous System Metastasis

National Taiwan University Hospital1 site in 1 country30 target enrollmentJanuary 13, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer With Central Nervous System Metastasis
Sponsor
National Taiwan University Hospital
Enrollment
30
Locations
1
Primary Endpoint
predict lung cancer metastasis and Bioindicators of treatment effect
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.

Registry
clinicaltrials.gov
Start Date
January 13, 2023
End Date
December 2027
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • A. Non-small cell lung cancer patients diagnosed with brain metastases or meningeal metastases on brain computed tomography (CT) or magnetic resonance (MRI) images.
  • B. Patients with non-small cell lung cancer who are about to undergo surgical brain surgery, such as brain tumor resection, lumbar abdominal drainage, Euclidean storage, or ventriculoperitoneal drainage.

Exclusion Criteria

  • A. Non-small cell lung cancer patients without brain metastases or meningeal metastases.
  • B. Physical condition does not allow surgical removal of the tumor.

Outcomes

Primary Outcomes

predict lung cancer metastasis and Bioindicators of treatment effect

Time Frame: follow 3 years

Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.

Study Sites (1)

Loading locations...

Similar Trials